Answers are grounded in this paper and cite their sources.
Objective To investigate the expression and clinical significance of CD90 and CD177 in cervical cancer. Methods Cases of cervical cancer (n = 102), cervical intraepithelial neoplasia (CIN, n = 52), and benign uterine disease (n = 50) were selected. The positive rates of CD90 and CD177 in the cervical tissues were detected, and the significance of CD90 and CD177 expression was analyzed. Results The positive rate of CD90 in normal cervical tissue, CIN, and cervical cancer was 3.7%, 36.5%, and 79.4% respectively. The respective positive rates of CD177 were 1.8%, 32.7%, and 74.5%. The positive rates of CD90 and CD177 in cervical cancer tissues were the highest, followed by CIN tissues (P < 0.05). Multivariate analysis showed that pathological grade, lymph node metastasis, and tumor diameter were independent risk factors affecting the expression of CD90 and CD177 (each P < 0.05). There was a moderate positive correlation between CD90 and CD177 expression (r = 0.679, P = 0.003). The overall survival rate of 102 patients with cervical cancer was 64.7%. There were 33 deaths in the CD90 positive group and 3 in the negative group. The overall survival rates were 59.3% and 85.7% in the CD90 and negative group, respectively. There were 33 deaths in the CD177 positive group and 3 in the negative group. The overall survival rates were 56.6% and 88.5%, respectively. The difference was statistically significant. Conclusion The expression of CD90 and CD177 has some adverse effects on the clinicopathological parameters of cervical cancer. The positive expression of CD90 and CD177 is a risk factor for poor prognosis.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: